MXPA02012792A - Composicion y forma de de dosificacion para liberacion gastrica retardada de alendronato y/u otros bis-fosfonatos. - Google Patents
Composicion y forma de de dosificacion para liberacion gastrica retardada de alendronato y/u otros bis-fosfonatos.Info
- Publication number
- MXPA02012792A MXPA02012792A MXPA02012792A MXPA02012792A MXPA02012792A MX PA02012792 A MXPA02012792 A MX PA02012792A MX PA02012792 A MXPA02012792 A MX PA02012792A MX PA02012792 A MXPA02012792 A MX PA02012792A MX PA02012792 A MXPA02012792 A MX PA02012792A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage form
- alendronate
- bis
- composition
- phosphonates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invencion provee una composicion farmaceutica compactada para la administracion oral a un paciente que se expande al contacto con el fluido gastrico para retener una forma de dosificacion en el estomago del paciente durante un periodo de tiempo extendido, la formulacion comprende un hidrogel no hidratado, un superdesintegrante y acido tanico. La presente invencion tambien provee una forma de dosificacion farmaceutica que contiene un ingrediente activo, y la composicion farmaceutica compactada. La invencion tambien provee una forma de dosificacion adecuada para la administracion de un bis-fosfonato terapeutico tal como un alendronato al estomago de un paciente durante un periodo de tiempo extendido.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21383200P | 2000-06-23 | 2000-06-23 | |
US26043801P | 2001-01-09 | 2001-01-09 | |
US09/770,898 US6476006B2 (en) | 2000-06-23 | 2001-01-26 | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
PCT/US2001/020130 WO2002000204A1 (en) | 2000-06-23 | 2001-06-22 | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA02012792A true MXPA02012792A (es) | 2004-07-30 |
Family
ID=27395916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA02012792A MXPA02012792A (es) | 2000-06-23 | 2001-06-22 | Composicion y forma de de dosificacion para liberacion gastrica retardada de alendronato y/u otros bis-fosfonatos. |
Country Status (12)
Country | Link |
---|---|
US (2) | US6476006B2 (es) |
EP (1) | EP1296657A1 (es) |
JP (1) | JP2004501186A (es) |
KR (1) | KR20030023879A (es) |
AU (2) | AU2001268719B2 (es) |
CA (1) | CA2412024A1 (es) |
CZ (1) | CZ2003211A3 (es) |
EA (1) | EA007247B1 (es) |
HU (1) | HUP0301400A3 (es) |
IL (1) | IL153443A0 (es) |
MX (1) | MXPA02012792A (es) |
WO (1) | WO2002000204A1 (es) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7608640B2 (en) * | 1999-03-02 | 2009-10-27 | Jallal Messadek | Glycine betaine and its use |
US6476006B2 (en) * | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
EP1416919A1 (en) * | 2001-07-17 | 2004-05-12 | Teva Pharmaceutical Industries Ltd. | Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
US20040052843A1 (en) * | 2001-12-24 | 2004-03-18 | Lerner E. Itzhak | Controlled release dosage forms |
BR0215413A (pt) * | 2001-12-24 | 2004-12-14 | Teva Pharma | Formula dosada com um comprimido central de ingrediente ativo encapado em uma capa anular prensada de material em pó ou granulado e processo e conjunto de ferramentas para a sua produção |
BE1015608A6 (fr) * | 2003-07-15 | 2005-06-07 | Messadek Jallal | Traitement des arterites. |
WO2003095029A1 (en) | 2002-05-10 | 2003-11-20 | F. Hoffmann-La Roche Ag | Bisphosphonic acid for the treatment and prevention of osteoporosis |
US20050026871A1 (en) * | 2002-07-17 | 2005-02-03 | Moshe Flashner-Barak | Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative |
DE20321698U1 (de) | 2002-12-16 | 2008-12-24 | Teva Pharmaceutical Industries Ltd. | Medikament zur Erhöhung der Bioverfügbarkeit von Alendronat oder einem anderen Bisphosphonat durch Verabreichen einer Vordosis eines Vitamin-D-Derivats |
RU2315603C2 (ru) | 2002-12-20 | 2008-01-27 | Ф.Хоффманн-Ля Рош Аг | Композиция с высокой дозой ибандроната |
US6846497B2 (en) * | 2003-01-30 | 2005-01-25 | National Starch And Chemical Investment Holding Corporation | Rapidly expanding starches with altered crystalline structure |
SI21403A (sl) * | 2003-02-27 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Farmacevtska oblika z alendronsko kislino, njenimi solmi ali estri ter postopek za njeno pripravo |
DE602004003577T2 (de) * | 2003-04-17 | 2007-09-20 | Jallal Messadek | Flottierende orale Formulierungen mit kontrollierter Freisetzung von Betain |
KR101192722B1 (ko) * | 2003-04-24 | 2012-10-18 | 자고텍 아게 | 정해진 핵 위치를 가지는 서방성 정제 |
US20060128657A1 (en) * | 2003-08-04 | 2006-06-15 | Jallal Messadek | Selected betaines and their uses |
JP2005132803A (ja) * | 2003-10-31 | 2005-05-26 | Ono Pharmaceut Co Ltd | 胃内滞留固形剤 |
US6783772B1 (en) * | 2003-12-12 | 2004-08-31 | Sanjeev Khandelwal | Pharmaceutical preparations containing alendronate sodium |
US20080286359A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US7645460B2 (en) * | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
US20080287400A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
BE1016128A6 (fr) * | 2004-07-22 | 2006-03-07 | Messadek Jallal | Combinaisons therapeutiques |
FR2874325B1 (fr) * | 2004-08-19 | 2006-10-20 | Sanofi Synthelabo | Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine |
WO2006050581A2 (en) * | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
US20060134190A1 (en) * | 2004-12-16 | 2006-06-22 | Banner Pharmacaps Inc. | Formulations of bisphosphonate drugs with improved bioavailability |
WO2006086856A1 (en) | 2005-02-15 | 2006-08-24 | Messadek, Jallal | Combination therapeutic compositions and method of use |
JP2009506978A (ja) * | 2005-04-27 | 2009-02-19 | メッサデク ジャアル | インスリン類の併用 |
US7765785B2 (en) * | 2005-08-29 | 2010-08-03 | Kashmerick Gerald E | Combustion engine |
WO2007079082A2 (en) * | 2005-12-30 | 2007-07-12 | Advancis Pharmaceutical Corporation | Gastric release pulse system for drug delivery |
CA2657435A1 (en) | 2006-07-10 | 2008-07-03 | Medipacs, Inc. | Super elastic epoxy hydrogel |
SI2049123T2 (sl) | 2006-08-03 | 2016-10-28 | Horizon Pharma Ag | Zdravljenje revmatoznih bolezni z zadržanim sproščanjem glukokortikoida |
WO2008020305A2 (en) * | 2006-08-17 | 2008-02-21 | Aurobindo Pharma Limited | Solid dosage forms of bisphosphonic acids |
EP1935411A1 (en) * | 2006-12-15 | 2008-06-25 | Campina Nederland Holding B.V. | Slow release excipient and its use |
DE602007007361D1 (de) * | 2006-12-15 | 2010-08-05 | Campina Nederland Holding Bv | Hilfsstoff mit verzögerter freisetzung und seine verwendung |
US8974801B2 (en) * | 2006-12-21 | 2015-03-10 | Amphastar Pharmaceuticals Inc. | Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate |
MX2010001629A (es) * | 2007-08-10 | 2010-08-09 | Alessandro Sannino | Hidrogeles de polimero y metodos de preparacion de los mismos. |
US20090118238A1 (en) * | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
WO2009065193A1 (en) * | 2007-11-21 | 2009-05-28 | Jallal Messadek | Treatment of aspirin resistance with betaine and/or betaine enriched molasses |
JP2011505520A (ja) | 2007-12-03 | 2011-02-24 | メディパックス インコーポレイテッド | 流体計量供給装置 |
US9457048B2 (en) | 2008-02-05 | 2016-10-04 | Wellosophy Corporation | Absorbent ingestible agents and associated methods of manufacture and use |
EP2210585A1 (en) | 2009-01-16 | 2010-07-28 | Exelgyn | SPRM pharmaceutical compositions methods of treatment using them |
US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
AU2010278860B2 (en) | 2009-07-31 | 2016-05-26 | Thar Pharma, Llc | Crystallization method and bioavailability |
US9238102B2 (en) | 2009-09-10 | 2016-01-19 | Medipacs, Inc. | Low profile actuator and improved method of caregiver controlled administration of therapeutics |
FR2952937B1 (fr) * | 2009-11-20 | 2013-02-08 | Chaire Europeenne De Chimie Now Pour Un Developpement Durable | Nouvelles resines de type phenoplastes obtenues a partir de composes phenoliques et de durcisseurs macromoleculaire portant des fonctions aldehydes |
US20110172637A1 (en) * | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Drug delivery device including tissue support structure |
US20110172639A1 (en) * | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Device and method for delivery of microneedle to desired depth within the skin |
US20110172609A1 (en) * | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Microneedle component assembly for drug delivery device |
US20110172645A1 (en) * | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Wearable drug delivery device including integrated pumping and activation elements |
US9500186B2 (en) | 2010-02-01 | 2016-11-22 | Medipacs, Inc. | High surface area polymer actuator with gas mitigating components |
WO2012061556A1 (en) | 2010-11-03 | 2012-05-10 | Flugen, Inc. | Wearable drug delivery device having spring drive and sliding actuation mechanism |
US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
KR101324425B1 (ko) * | 2011-07-22 | 2013-11-01 | 동아에스티 주식회사 | 증가된 비스포스포네이트의 생체이용률을 가지는 경구투여 약제 |
CN104302689A (zh) | 2012-03-14 | 2015-01-21 | 麦德医像公司 | 含有过量活性分子的智能聚合物材料 |
EP3091962B1 (en) * | 2013-12-05 | 2022-06-08 | Epitomee Medical Ltd. | Retentive devices and systems for in-situ release of pharmaceutical active agents |
US9617230B2 (en) | 2014-12-22 | 2017-04-11 | Farmington Pharma Development | Creatine prodrugs, compositions and methods of use thereof |
US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
JP6823539B2 (ja) * | 2017-05-26 | 2021-02-03 | 株式会社ファンケル | 胃内滞留性錠剤 |
CA3082184A1 (en) | 2017-12-01 | 2019-06-06 | Ultragenyx Pharmaceutical Inc. | Creatine prodrugs, compositions and methods of use thereof |
US11826473B2 (en) * | 2018-01-11 | 2023-11-28 | Sawai Pharmaceutical Co., Ltd. | Orally disintegrating tablet coated with film |
JP7044649B2 (ja) * | 2018-06-28 | 2022-03-30 | 株式会社ファンケル | 胃内浮遊錠剤 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2996431A (en) | 1953-12-16 | 1961-08-15 | Barry Richard Henry | Friable tablet and process for manufacturing same |
US3139383A (en) | 1961-06-26 | 1964-06-30 | Norton Co | Encapsulated time release pellets and method for encapsulating the same |
US3995058A (en) | 1973-12-12 | 1976-11-30 | Miles Laboratories, Inc. | Treatment of ethanol withdrawal symptoms with levodopa |
US4167558A (en) | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
US4140755A (en) | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
FR2470599A1 (fr) | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
DE3016289A1 (de) | 1980-04-28 | 1981-10-29 | Henkel KGaA, 4000 Düsseldorf | Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren |
US4764380A (en) | 1982-03-22 | 1988-08-16 | Alza Corporation | Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills |
US4434153A (en) | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
IT1201087B (it) | 1982-04-15 | 1989-01-27 | Gentili Ist Spa | Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche |
US4721613A (en) | 1982-12-13 | 1988-01-26 | Alza Corporation | Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use |
IT1196315B (it) | 1984-10-29 | 1988-11-16 | Gentili Ist Spa | Procedimento per la preparazione di acidi difosfonici |
US4758436A (en) | 1985-05-29 | 1988-07-19 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
US4767627A (en) | 1985-05-29 | 1988-08-30 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
US4704285A (en) | 1985-11-18 | 1987-11-03 | The Dow Chemical Company | Sustained release compositions comprising hydroxypropyl cellulose ethers |
US4756911A (en) | 1986-04-16 | 1988-07-12 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US4752470A (en) | 1986-11-24 | 1988-06-21 | Mehta Atul M | Controlled release indomethacin |
US4853229A (en) | 1987-10-26 | 1989-08-01 | Alza Corporation | Method for adminstering tiny pills |
US4983398A (en) | 1987-12-21 | 1991-01-08 | Forest Laboratories, Inc. | Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates |
US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US4922007A (en) | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
US5356887A (en) * | 1990-01-31 | 1994-10-18 | Merck & Co., Inc. | Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids |
US5019651A (en) | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
JPH04346919A (ja) | 1991-05-27 | 1992-12-02 | Shin Etsu Chem Co Ltd | 徐放性錠剤の製造方法 |
US5198229A (en) | 1991-06-05 | 1993-03-30 | Alza Corporation | Self-retaining gastrointestinal delivery device |
TW257765B (es) | 1993-08-25 | 1995-09-21 | Merck & Co Inc | |
US5431920A (en) * | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
JP3601102B2 (ja) | 1995-03-15 | 2004-12-15 | ブラザー工業株式会社 | インクジェット式印刷記録装置と印字システム |
AU6148396A (en) | 1995-06-06 | 1996-12-24 | Merck & Co., Inc. | Disodium alendronate formulations |
US5840756A (en) | 1995-07-21 | 1998-11-24 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition of L-DOPA ester |
EP0761209A3 (en) | 1995-09-01 | 1998-02-04 | J.B. Chemicals & Pharmaceuticals Ltd. | Controlled release formulations of ranitidine |
US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
IT1282650B1 (it) | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
DE19615812A1 (de) | 1996-04-20 | 1997-10-23 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
ES2248908T7 (es) | 1997-06-06 | 2014-11-24 | Depomed, Inc. | Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles |
HUP0002490A2 (hu) | 1997-07-23 | 2000-12-28 | Perio Products Ltd. | Csersav-polimer kompozíciók gyógyászati anyagok szabályozott leadására, különösen a szájüregben |
WO1999007342A1 (en) | 1997-08-11 | 1999-02-18 | Alza Corporation | Prolonged release active agent dosage form adapted for gastric retention |
IN186245B (es) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
US6121253A (en) * | 1998-11-20 | 2000-09-19 | Merck Frosst Canada & Co. | Prostaglandin conjugates for treating or preventing bone disease |
US6476006B2 (en) * | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
US6863901B2 (en) * | 2001-11-30 | 2005-03-08 | Collegium Pharmaceutical, Inc. | Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration |
-
2001
- 2001-01-26 US US09/770,898 patent/US6476006B2/en not_active Expired - Fee Related
- 2001-06-22 EP EP01946706A patent/EP1296657A1/en not_active Withdrawn
- 2001-06-22 HU HU0301400A patent/HUP0301400A3/hu unknown
- 2001-06-22 AU AU2001268719A patent/AU2001268719B2/en not_active Expired - Fee Related
- 2001-06-22 IL IL15344301A patent/IL153443A0/xx unknown
- 2001-06-22 CA CA002412024A patent/CA2412024A1/en not_active Abandoned
- 2001-06-22 EA EA200300045A patent/EA007247B1/ru active Application Revival
- 2001-06-22 WO PCT/US2001/020130 patent/WO2002000204A1/en not_active Application Discontinuation
- 2001-06-22 JP JP2002504986A patent/JP2004501186A/ja active Pending
- 2001-06-22 AU AU6871901A patent/AU6871901A/xx active Pending
- 2001-06-22 MX MXPA02012792A patent/MXPA02012792A/es unknown
- 2001-06-22 KR KR1020027017536A patent/KR20030023879A/ko not_active Application Discontinuation
- 2001-06-22 CZ CZ2003211A patent/CZ2003211A3/cs unknown
-
2003
- 2003-04-22 US US10/420,403 patent/US20030203878A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6476006B2 (en) | 2002-11-05 |
CZ2003211A3 (en) | 2004-03-17 |
US20030203878A1 (en) | 2003-10-30 |
AU6871901A (en) | 2002-01-08 |
EA200300045A1 (ru) | 2003-08-28 |
KR20030023879A (ko) | 2003-03-20 |
EA007247B1 (ru) | 2006-08-25 |
JP2004501186A (ja) | 2004-01-15 |
HUP0301400A2 (hu) | 2003-09-29 |
CA2412024A1 (en) | 2002-01-03 |
HUP0301400A3 (en) | 2005-02-28 |
EP1296657A1 (en) | 2003-04-02 |
US20020015733A1 (en) | 2002-02-07 |
AU2001268719B2 (en) | 2006-04-27 |
IL153443A0 (en) | 2003-07-06 |
WO2002000204A1 (en) | 2002-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA02012792A (es) | Composicion y forma de de dosificacion para liberacion gastrica retardada de alendronato y/u otros bis-fosfonatos. | |
MXPA02012793A (es) | Composicion de dilatacion rapida para la retencion gastrica y la liberacion controlada de agentes terapeuticos y formas de dosificacion de la composicion. | |
WO2006039692A3 (en) | Modified release ibuprofen dosage form | |
PL334656A1 (en) | Dosage forms and methods of achieving betterement in cases of erection disorderamong male patients | |
CO4600739A1 (es) | Formulaciones liquidas orales a base de alendronato | |
DK0862416T3 (da) | Ikke-polymert indgivelsessystem med forhalet frigørelse | |
TW200640486A (en) | Composition | |
PT1256340E (pt) | Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson | |
IL174562A0 (en) | Oros push-stick for controlled delivery of active agent | |
DE69521688T2 (de) | Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung | |
NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
MXPA05010196A (es) | Nuevas formulaciones y su uso. | |
NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
MY144021A (en) | Pharmaceutical delivery system | |
IS7006A (is) | Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd | |
AP2003002763A0 (en) | Controlled release formulations for oral administration | |
HK1060691A1 (en) | Ion-strength independent sustained release pharmaceutical formulation | |
MXPA04004907A (es) | Composiciones de acetaminofen. | |
MY137570A (en) | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease | |
ECSP045056A (es) | Composiciones de valdecoxib de disgregación intraoral preparadas mediante un procedimiento de desecación por pulverizacion | |
AR023151A1 (es) | Preparado farmaceutico que contiene como principio activo, por lo menos una parte de acido acetilsalicilico | |
MY145885A (en) | Controlled release formulations for oral administration |